Dr Reddy’s Laboratories will hold a board meeting to consider recommending a final dividend for the financial year 2025-26, the company disclosed in a regulatory filing on 16 April 2026.
The intimation was submitted to the National Stock Exchange of India (Scrip Code: DRREDDY), BSE Limited (Scrip Code: 500124), New York Stock Exchange Inc. (Stock Code: RDY), and NSE IFSC Ltd. (Stock Code: DRREDDY).
The announcement follows prior intimation dated 23 March 2026, where the company had flagged the forthcoming board meeting. The filing does not specify the timing of the board meeting or the quantum of dividend under consideration.
The recommendation for a final dividend, if approved by the board, would be subject to shareholder ratification at the annual general meeting. Final dividend proposals are typically presented after the completion of a full financial year’s results and analysis.
Dr Reddy’s Laboratories is a major pharmaceutical company listed on multiple exchanges globally. The company is registered in Telangana with headquarters in Hyderabad.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).